Outcomes in children with central nervous system tumors disseminated at presentation: a large single-center experience

被引:2
|
作者
Kirkman, Matthew A. [1 ,2 ]
Hayward, Richard [1 ]
Phipps, Kim [1 ]
Aquilina, Kristian [1 ]
机构
[1] Great Ormond St Hosp Sick Children, Dept Neurosurg, London WC1N 3JH, England
[2] Natl Hosp Neurol & Neurosurg, Victor Horsley Dept Neurosurg, Queen Sq, London, England
关键词
Central nervous system tumors; Event-free survival; Overall survival; Recurrence; LEPTOMENINGEAL DISSEMINATION; PILOCYTIC ASTROCYTOMA; MEDULLOBLASTOMA; CHEMOTHERAPY; DIAGNOSIS;
D O I
10.1007/s00381-018-3871-1
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Purpose Children with disseminated central nervous system (CNS) tumors have worse outcomes than those with solitary disease, but outcomes of disease dissemination at initial presentation have not been systematically studied and compared across tumor groups to date. We evaluated the impact of tumor dissemination at presentation on management and clinical outcomes in a cohort of consecutively treated children in a single neurosurgical unit over a 14-year period. Methods Method used was a retrospective review of data on children presenting to Great Ormond Street Hospital, London, UK, with medulloblastoma, primitive neuroectodermal tumor, atypical teratoid rhabdoid tumor, pilocytic astrocytoma, and ependymoma between 2003 and 2016 inclusive. Uni- and multi-variate analyses were performed to evaluate a range of outcome measures. Results Three-hundred sixty-one children were identified in total, 53 with disease dissemination at presentation (M:F = 34:19, median age = 3.8 years, range = 7 days-15.6 years) and 308 with solitary tumors (M:F = 161:147, median age = 5.8 years, range = 1 day-16.9 years). Median follow-up was similar irrespective of dissemination status (disseminated tumor 64.0 months, range = 5.2-152.0 months; solitary tumor 74.5 months, range = 4.7-170.1 months; P > 0.05). In multivariate analyses, tumor type and dissemination status at presentation were significantly associated with overall survival (P < 0.0001), risk of recurrence/disease progression (P < 0.01), and event-free survival (P < 0.0001). Subtotal resection was associated with shorter time to recurrence/disease progression (P < 0.01) and worse event-free (P < 0.0001) but not overall survival, whereas treatment with chemotherapy and radiotherapy were associated with improved overall (Ps < 0.0001) and event-free survival (Ps < 0.05). Differences between tumor groups were evident. Conclusions Dissemination status at initial presentation significantly affects outcomes in children with CNS tumors.
引用
收藏
页码:2259 / 2267
页数:9
相关论文
共 50 条
  • [1] Outcomes in children with central nervous system tumors disseminated at presentation: a large single-center experience
    Matthew A. Kirkman
    Richard Hayward
    Kim Phipps
    Kristian Aquilina
    Child's Nervous System, 2018, 34 : 2259 - 2267
  • [2] Presentation and symptom interval in children with central nervous system tumors. A single-center experience
    Stocco, Chiara
    Pilotto, Chiara
    Passone, Eva
    Nocerino, Agostino
    Tosolini, Raffaello
    Pusiol, Anna
    Cogo, Paola
    CHILDS NERVOUS SYSTEM, 2017, 33 (12) : 2109 - 2116
  • [3] Presentation and symptom interval in children with central nervous system tumors. A single-center experience
    Chiara Stocco
    Chiara Pilotto
    Eva Passone
    Agostino Nocerino
    Raffaello Tosolini
    Anna Pusiol
    Paola Cogo
    Child's Nervous System, 2017, 33 : 2109 - 2116
  • [4] A single-center experience of central nervous system tumors in children under three years old
    Wang, Junhua
    Wang, Chuanwei
    Huang, Zhimin
    Zhang, Zhihua
    Zhang, Yuqi
    FRONTIERS IN PEDIATRICS, 2024, 12
  • [5] Clinical factors, management, and outcomes of children under 3 years old with central nervous system tumors: single-center experience
    Eker, Nursah
    Tokuc, Gulnur
    Sarisaltik, Alican
    Dagcinar, Adnan
    Gul, Dilek
    Atasoy, Beste Melek
    Yilmaz, Baris
    Tas, Burcu Tufan
    CHILDS NERVOUS SYSTEM, 2024, 40 (08) : 2311 - 2320
  • [6] Vasculitis in the Central Nervous System: Treatment and Outcomes in a Large Single-Center Cohort
    Hoshina, Yoji
    Delic, Alen
    Wong, Ka-Ho
    Lyden, Stephanie
    Kadish, Robert
    Clardy, Stacey
    NEUROLOGY, 2023, 100 (17)
  • [7] Nimotuzumab therapy in the treatment of pediatric central nervous system tumors: single-center experience
    Susam-Sen, Hilal
    Varan, Ali
    Bajin, Inci
    Gocmen, Rahsan
    Aydin, Burca
    Yalcin, Bilgehan
    Kurucu, Nilgun
    Kutluk, Tezer
    Bayhan, Turhan
    Akyuz, Canan
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2021, 394 (08) : 1769 - 1777
  • [8] Pediatric Central Nervous System Tumors: A Single-center Experience From 1989 to 2009
    Pinho, Ricardo Silva
    Andreoni, Solange
    Silva, Nasjla Saba
    Cappellano, Andrea Maria
    Masruha, Marcelo Rodrigues
    Cavalheiro, Sergio
    Pereira Vilanova, Luiz Celso
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2011, 33 (08) : 605 - 609
  • [9] The use of bevacizumab in primary malignant tumors of the central nervous system: A single-center experience
    Pehlivan, Metin
    Ekenel, Meltem
    MEDICINE, 2023, 102 (30) : E34286
  • [10] Nimotuzumab therapy in the treatment of pediatric central nervous system tumors: single-center experience
    Hilal Susam-Sen
    Ali Varan
    İnci Bajin
    Rahşan Göçmen
    Burca Aydın
    Bilgehan Yalcin
    Nilgun Kurucu
    Tezer Kutluk
    Turhan Bayhan
    Canan Akyuz
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2021, 394 : 1769 - 1777